U.S., July 14 -- ClinicalTrials.gov registry received information related to the study (NCT07699770) titled 'Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial' on April 15.
Brief Summary: This study is a multicenter, prospective, randomized, double-blind, placebo-controlled exploratory investigation conducted in China.
Study Start Date: June 15
Study Type: INTERVENTIONAL
Condition:
Neuromyelitis Optica Spectrum Disorders (NMOSD)
Neuropathic Pain
Intervention:
DRUG: Crisugabalin
Crisugabalin 20-40mg bid
DRUG: Placebo+Crisugabalin
Placebo+Crisugabalin
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Tang-Du Hospital
Published by HT Digital Content Services with permission from...